Palatin Technologies, Inc. ( NYSE: PTN) Q1 2025 Earnings Conference Call November 14, 2024 11:00 AM ET Carl Spana - CEO and President Stephen Wills - CFO, COO, Treasurer and Secretary ...
Eli Lilly's Phase 3 study shows tirzepatide significantly cuts type 2 diabetes risk and supports 22.9% average weight loss in adults over three years.
Wolfe Research analyst Alexandria Hammond initiated coverage of Johnson & Johnson (JNJ) with an Outperform rating and $190 price target ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback